Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for C4 Therapeutics, Inc. (CCCC : NSDQ)

• Company Description    C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics Inc. is based in WATERTOWN, Mass. Number of Employees: 110

• Price / Volume Information    Yesterday's Closing Price: $2.73 Daily Weekly Monthly 20 Day Moving Average: 1,033,386 shares Shares Outstanding: 71.17 (millions) Market Capitalization: $194.30 (millions) Beta: 2.98 52 Week High: $7.22 52 Week Low: $1.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.17% 14.07% 12 Week 89.58% 72.13% Year To Date -24.17% -32.29%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 490 Arsenal Way Suite 120 - Watertown,MA 02472 USA ph: 617-231-0700 fax: - csolberg@c4therapeutics.com http://www.c4therapeutics.com

• General Corporate Information    Officers Andrew J. Hirsch - President and Chief Executive Officer Ronald Cooper - Chairman Kendra R. Adams - Chief Financial Officer and Treasurer Laura Bessen - Director Bruce Downey - Director Peer Information C4 Therapeutics, Inc. (CORR.) C4 Therapeutics, Inc. (RSPI) C4 Therapeutics, Inc. (CGXP) C4 Therapeutics, Inc. (BGEN) C4 Therapeutics, Inc. (GTBP) C4 Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 12529R107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 10/30/25 Share - Related Items Shares Outstanding: 71.17 Most Recent Split Date: (:1) Beta: 2.98 Market Capitalization: $194.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/30/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.12 Price/Cash Flow: - Price / Sales: 5.67 EPS Growth vs. Year Ago Period: -42.31% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -46.17% vs. Previous Quarter: -10.71% ROE 06/30/25 - -53.91 03/31/25 - -45.86 12/31/24 - -43.70 ROA 06/30/25 - -33.26 03/31/25 - -28.96 12/31/24 - -27.99 Current Ratio 06/30/25 - 5.06 03/31/25 - 5.70 12/31/24 - 5.71 Quick Ratio 06/30/25 - 5.06 03/31/25 - 5.70 12/31/24 - 5.71 Operating Margin 06/30/25 - -325.88 03/31/25 - -259.60 12/31/24 - -295.96 Net Margin 06/30/25 - -325.88 03/31/25 - -259.60 12/31/24 - -295.96 Pre-Tax Margin 06/30/25 - -325.50 03/31/25 - -259.27 12/31/24 - -295.60 Book Value 06/30/25 - 2.45 03/31/25 - 2.75 12/31/24 - 3.06 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©